More specifically, there were patients with CIDP and Guillain–Barré syndrome (GBS) that were positive for anti-CASPR1 antibodies and negative for anti-CNTN1 or NF155 antibodies. The gene discussed is CNTNAP1; the disease is chronic inflammatory demyelinating polyradiculoneuropathy.